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Abstract
In this review we report novel sensitive imaging biomarkers for Parkinson’s disease (PD) and its
atypical variants. Diffusion tensor imaging and transcranial brain sonography are potentially promising
techniques that can differentiate typical PD from atypical variants (multiple system atrophy and
progressive supranuclear palsy) and from benign tremor disorders. Non-motor symptoms, such as
dementia, depression, and sleep disruption, are often more distressing to PD patients than their
slowness and stiffness. Dopamine replacement treatment can also lead to complications such as
dyskinesias, impulse control disorders, and psychosis. Recent positron emission tomography studies
have helped to clarify the physiopathological mechanisms underlying dementia and compulsive
gambling in PD and provide a rationale for therapeutic strategies.
Introduction and context
Parkinson’s disease (PD), the second most common
neurodegenerative disorder, is associated with the pre-
sence of intra-neuronal fibrillar aggregates of a-synuclein
called Lewy bodies and the degeneration of dopaminer-
gic neurons in the substantia nigra (SN) pars compacta.
Clinically, patients show a combination of motor
symptoms (rest tremor, bradykinesia, rigidity) and
non-motor features (dementia, sleep disorders, fatigue,
depression) caused by dopamine depletion and, to a
lesser extent, dysfunction of other neurotransmitters. The
role of non-dopaminergic dysfunction in PD, however,
remains unclear, and a better understanding of this area
is currently one of the main key targets for PD research.
The diagnosis of PD is still based on clinical symptoms
andsigns.However,particularlyattheonsetofsymptoms,
it may be difficult to discriminate between PD, essential
and dystonic tremors, and atypical parkinsonian variants
with alternative pathologies, such as multiple system
atrophy and progressive supranuclear palsy.
A minority of patients with PD develop compulsive
behaviours such as pathological gambling, compulsive
shopping, and hypersexuality while receiving dopamine
replacement treatment. The anatomical and neurochem-
ical substrates of these behavioural disturbances in PD
remain to be established.
Structural and functional neuroimaging techniques
provide powerful tools to investigate in vivo the
physiopathological mechanisms underlying PD. Mag-
netic resonance imaging (MRI) and, more recently,
transcranial sonography (TCS) have been used to detect
alterations in nigral structure. New MRI techniques,
including diffusion tensor imaging (DTI) and diffusion
tensor tractography (DTT), enable evaluation of the
integrity of neuronal connectivity in the brain. Positron
emission tomography (PET) and single photon emission
computed tomography (SPECT) are radiotracer-based
techniques and can be employed in PD to evaluate: (a)
presynaptic dopaminergic terminal function; (b) post-
synaptic dopamine receptor function; (c) dopamine
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(d) dysfunction of non-dopaminergic pathways.
Recent advances
A correct diagnosis of PD is vital in order to establish the
correct prognosis of the disease, to predict its response to
therapy and last, but not least, to ensure appropriate
recruitment of patients into clinical trials testing the
efficacy of new putative neuroprotective and sympto-
matic therapeutic agents. PD is associated with striatal
dopamine deficiency and so assessment of presynaptic
striatal dopamine terminal function with either PET or
SPECT can support or refute the diagnosis. A recent paper
reports the results of a direct comparison of
123I-FP-CIT
SPECT, a marker of dopamine transporter binding, and
18F-dopa PET, a marker of dopamine storage capacity, in
28 patients with clinically probable PD [1]. These
imaging modalities were both able to reliably discrimi-
nate early PD patients from healthy controls. Detection
of reduced dopaminergic function in the putamen
contralateral to the more symptomatic side showed
100% specificity and sensitivity for PD. Longitudinal
follow-up studies are required to compare the sensitivity
of the two techniques for monitoring progression of
nigrostriatal degeneration in PD.
A single 15 minute scan 75 minutes after injection of
18F-
dopa seems to be sufficient to discriminate PD patients
from healthy controls [2]. The researchers at the Turku
PET Centre, Finland analyzed PET images of
18F-dopa
uptake with both a traditional method (Patlak graphical
analysis of data collected 15-90 minutes after injection)
and a region-to-reference ratio (striatal-to-occipital ratio,
or SOR) calculated 75-90 minutes after injection. Both
methods were able to separate 84 unmedicated PD
patients from 21 healthy volunteers. In principle, by
shortening the scanning time, a 75-90 minute SOR
analysis may offer several advantages, including less
discomfort for the patient and reduced subject move-
ment during the scan. It remains to be established
whether the snapshot method is sensitive to longitudinal
changes in
18F-dopa uptake and whether it can be used in
the long-term evaluation of disease progression.
A recent prospective blinded study has assessed the
specificity and sensitivity of TCS for the differential
diagnosis of PD [3]. TCS measures brain tissue echo-
genicity through the intact skull and has been used for
more than 10 years to discriminate PD from other
movement disorders [4-6]. In PD patients, the typical
TCS finding is increased echogenicity from the lateral
midbrain, probably reflecting increased iron deposition
in the SN [3].
In a prospective study, 60 patients with soft signs of
parkinsonism had baseline TCS and then were clinically
assessed every 3 months for 1 year. At the end of the
follow-up period a clinical and/or SPECT/PET diagnosis
was made in 53 patients. Thirty-nine were classified as
having PD, ten as having atypical parkinsonian syn-
drome, and four had neither of these two conditions.
Compared to the final diagnosis, the sensitivity of TCS at
baseline was 90.7% and the specificity was 82.4%. The
positive predictive value of TCS for PD was 92.9% with a
classification accuracy of 88.3%.
This is a promising result, although there are difficulties
with the diagnostic use of TCS. First, increased SN
echogenicity has also been reported in 17% of patients
with essential tremor [7], 40% of depressed patients
without signs of PD [8], and in 10% of age-matched
healthy volunteers [9], suggesting the specificity of TCS is
suboptimal. Second, while most subjects have a suitable
preauricular acoustic bone window, this is not always the
case. Finally, patients with severe tremor have to be
excluded because movement artefact prevents reliable
interpretation of the images. If the presence of tremor
interferes with the examination, it could represent a
limitation of this method in clinical practice as most PD
patients have this symptom.
Assessment of regional fractional anisotropy (FA) within
nigrostriatal structures with DTI provides another non-
invasive biomarker that can be used to detect PD. FA is a
measure of the directional diffusivity of water in tissues
and provides information on the integrity of tracts in the
cerebral white matter and grey matter. In a recent study,
FA in the SN was measured in 14 untreated early stage
PD patients and 14 healthy volunteers matched for age
and gender [10]. FA values in the SN were reduced in all
the PD patients compared to the control group. The
greatest difference between the two groups was observed
in the caudal partof the SN. The findings are in agreement
with post-mortem studies, which show greater cell loss in
the ventro-caudal SN compared with the rostral segment
of this structure.
The DTI approach enabled accurate discrimination of
individual subjects; PD patients were distinguished from
the healthy volunteers on the basis of their FA value in
the caudal part of the SN with 100% sensitivity and
specificity. If confirmed in larger cohorts of PD patients,
these findings suggest that DTI could be as sensitive as
PET and SPECT for supporting a diagnosis of PD.
Cognitive impairment is one of the most disabling non-
motor complications of PD. The incidence of dementia
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healthy people and increases exponentially with age
[11]. Two recent papers have reported that amyloid
pathology, as measured by
11C-PIB PET, is infrequent in
PD patients with later onset dementia [12,13]. These
findings would suggest that that ß-amyloid deposition, a
pathological hallmark of Alzheimer’s disease, does not
contribute significantly to the pathogenesis of later
dementia in PD. However, this remains to be confirmed
in larger PD populations and disease subgroups. In
contrast, there is growing evidence that dopaminergic
and cholinergic dysfunction may play a role in causing
the cognitive deficits observed in PD patients [14-17].
Cholinergic dysfunction can be detected even in early PD
[17]. The effect of cholinesterase inhibitor (ChEI)
therapy on cerebral glucose metabolism has recently
been assessed in 12 PD patients with dementia [18].
ChEI treatment improved memory and induced signifi-
cant increases in cerebral metabolism in the left angular
gyrus (extending to the supramarginal area and left
superior and middle gyri), in the right superior, and left
middle orbitofrontal gyri. There were significant correla-
tions between improvements in Mini Mental State
Examination and increased cerebral metabolism in the
left supramarginal, orbitofrontal, and cingulate areas.
Recently, impulse control disorders and other beha-
vioural disturbances, which are generally associated with
exposure to dopaminergic medication – particularly
agonists, have surged to clinical importance as they can
devastate the quality of life for both PD patients and
their families. Affected cases have gambled away their life
savings on occasion. The mechanisms underlying the
development of these behavioural disturbances in PD
are currently under extensive investigation.
A recent SPECT study has reported that PD patients with
pathological gambling show overactivity in several areas
of the reward-related mesocorticolimbic circuitry during
resting condition [19]. Moreover, patients with patholo-
gical gambling also exhibit greater dopamine release
during gambling than control patients as demonstrated
by greater decreases in ventral striatum
11C-raclopride
binding in the former group of patients [20]. These
findings provide evidence that inappropriate brain
dopaminergic activity underlies the neurobiology of
impulse control disorders in PD. See Table 1 for an
overview of recent imaging findings in PD.
Implications for clinical practice
Both PET and SPECT have high sensitivity and specificity
for detecting striatal dopamine deficiency and can be
useful in supporting or refuting a diagnosis of PD, even
in early stages of disease. FP-CIT SPECT is now in
widespread use in Europe for this purpose and recently
became licensed for use in the US. PET is a more versatile
modality than SPECT but more expensive and less
available. It will maintain a crucial role in the under-
standing of the physiopathological mechanisms under-
lying PD and its complications, but it seems unlikely, at
this stage, that it will ever become a routine examination
for PD.
SN hyperechogenicity and measures of caudal FA with
DTI may prove to be as sensitive as PET and SPECT for
the early diagnosis of PD. Both techniques are non-
invasive, inexpensive and easy to implement. Never-
theless, these are preliminary findings and need to be
confirmed in larger cohorts of patients.
Cholinergic dysfunction plays an important role in
causing cognitive impairment in PD. Findings from
recent imaging studies provide a strong rationale for the
use of ChEI therapy in PD patients with cognitive
impairment, possibly even before the occurrence of
established dementia.
Table 1. Recent imaging findings in Parkinson’s disease
Study Topic Imaging technique Main findings
Eshuis et al., 2009 [1] Disease diagnosis
123FP-CIT SPECT
and
18F-dopa PET
Both techniques were equally able to distinguish PD patients from healthy
controls (100% specificity and sensitivity)
Jokinen et al., 2009 [2] Disease diagnosis
18F-dopa PET Striatal-to-occipital ratio calculated from 75-90 minutes after tracer injection
(short scan) can be used to separate PD patients from healthy volunteers
Gaenslen et al., 2008 [3] Disease diagnosis TCS The positive predictive value of TCS for PD was 92.9% with a classification
accuracy of 88.3%
Vaillancourt et al., 2009 [10] Disease diagnosis DTI Fractional anisotropy in the substantia nigra was reduced in the PD patients
compared to the control group
Lee et al., 2008 [18] Dementia in PD
18F-FDG PET Cholinesterase inhibitor therapy improved memory in PD patients with
dementia and induced significant increases in cerebral metabolism
Steeves et al., 2009 [20] Pathological gambling
11C-raclopride PET Evidence of increased ventral striatal dopamine release in PD patients with
pathological gambling
DTI, diffusion tensor imaging; PD, Parkinson’s disease; PET, positron emission tomography; SPECT, single photon emission computed tomography; TCS,
transcranial brain sonography.
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ChEI, cholinesterase inhibitor;
11C-PIB, N-methyl-[
11C]2-
(4
0-methylaminophenyl)-6-hydroxybenzothiazole; DTI,
diffusion tensor imaging; DTT, diffusion tensor tracto-
graphy; FA, fractional anisotropy;
18F-dopa; 6-L-
18F-
fluorodihydroxyphenylalanine;
123I-FP-CIT,
123I-labelled
N-(3-fluoropropyl)-2ß-carbomethoxy-3ß-(4-iodophe-
nyl)nortropane; MRI, magnetic resonance imaging; PD,
Parkinson’s disease; PET, positron emission tomography;
SN, substantia nigra; SOR, striatal-to-occipital ratio;
SPECT, single photon emission computed tomography;
TCS, transcranial brain sonography.
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